| WB | 1/1000-1/5000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDK 6; Cell division protein kinase 6; Crk 2; Cyclin dependent kinase 6; p40; PLSTIRE; STQTL11;;CDK6 |
| WB Predicted band size | 37 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human CDK6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇涉及CDK6抗体的研究文献概览(基于模拟生成内容，非真实文献)：
---
1. **"CDK6 regulates tumorigenesis through direct interaction with EMT transcription factors in breast cancer"**
*作者：Li, Y., et al. (2020)*
摘要：本研究利用特异性CDK6抗体(货号ABC123)通过免疫共沉淀和Western blot技术，揭示了CDK6与上皮间质转化(EMT)相关转录因子的直接互作机制，证实其在乳腺癌转移中的关键作用。
2. **"A novel CDK6 monoclonal antibody inhibits proliferation in hematologic malignancies"**
*作者：Garcia-Sanchez, A., et al. (2018)*
摘要：团队开发了一种高特异性抗人CDK6单克隆抗体(克隆号mAb-CD6-7B2)，通过体外实验证明其可阻断CDK6激酶活性，显著抑制白血病细胞系增殖，为靶向治疗提供新工具。
3. **"Tissue-specific expression profiling of CDK6 in pancreatic cancer using immunohistochemistry"**
*作者：Wang, X., et al. (2021)*
摘要：采用商业化CDK6抗体(品牌Cell Signaling, #13331)对胰腺癌组织进行免疫组化分析，发现CDK6高表达与患者预后不良相关，提示其作为生物标志物的潜力。
---
**备注**：以上文献信息为模拟生成，实际引用请通过PubMed或Google Scholar以“CDK6 antibody”及“CDK6 function”等关键词检索近年高被引论文。推荐关注《Nature Cell Biology》《Cancer Research》等期刊的相关研究。
CDK6 (Cyclin-Dependent Kinase 6) is a serine/threonine kinase that plays a pivotal role in regulating the cell cycle transition from the G1 phase to the S phase. It forms complexes with D-type cyclins (e.g., cyclin D1. D2. D3) to phosphorylate and inactivate the retinoblastoma (Rb) tumor suppressor protein, thereby promoting cell cycle progression and cellular proliferation. CDK6 is also implicated in transcriptional regulation and differentiation processes, particularly in hematopoietic and neuronal systems. Dysregulation of CDK6. through overexpression or genetic alterations, is frequently associated with cancer, including leukemias, lymphomas, and solid tumors, making it a potential therapeutic target.
CDK6 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to detect CDK6 levels in cell lines, tissues, or clinical samples. Specific CDK6 antibodies help distinguish it from its homolog CDK4. despite their structural similarities. Researchers employ these antibodies to explore CDK6's role in cancer biology, drug resistance, and the development of CDK4/6 inhibitors (e.g., palbociclib, ribociclib). Additionally, they aid in validating biomarker status in precision oncology and evaluating therapeutic responses in preclinical models. Proper validation of CDK6 antibodies for specificity and cross-reactivity is critical for reliable experimental outcomes.
×
